elinzanetant
Jump to navigation
Jump to search
Introduction
Investigational
Indications
- vasomotor symptoms of menopause
- improves sleep disturbances & menopause-related quality of life
Dosage
Adverse effects
- headache & fatigue most common (7-9% vs 2.5-2.6% for placebo)
- no serious adverse effect in clinical trial[1]
Mechanism of action
- selective neurokinin-1,3 receptor antagonist
More general terms
References
- ↑ 1.0 1.1 Pinkerton JV, Simon JA, Joffe H et al Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause. OASIS 1 and 2 Randomized Clinical Trials. JAMA. Published online August 22, 2024. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39172446 https://jamanetwork.com/journals/jama/fullarticle/2822766